Abeona Q2 net loss $12.1M; cash runway to 2Q 2023; VIITAL data expected late Q3/early Q4

ABEONA THERAPEUTICS INC.

2023-Q2 EPS reported $5.16 revenue$1,346,000

Net loss $12.1M ($2.08 loss/share) vs $15.2M ($3.93 loss/share) in Q2 2021.
Cash and investments $26.0M; net cash used in ops $9.0M; runway extended into Q2 2023.
License revenue $1.0M from Taysha sublicense milestone; R&D $6.7M, G&A $3.5M.
Phase 3 VIITAL study for EB-101 topline data expected late Q3/early Q4 2022; last patient monitoring mid-September.
License agreement with Ultragenyx for ABO-102 (MPS IIIA); Abeona eligible for tiered royalties and milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.